Free lookups: 1/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
1 of 3 free lookups remaining Upgrade
New search Medicine profile Loratadine

Clinical medicine profile

Loratadine

Therapeutic agent (verify pharmacological class)

POM
Evidence state General guidance Reviewed 14 Aug 2026
Route
See product SmPC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Pregnancy and lactation
  • hyper-sensitivity to loratadine
  • risk of serious ventricular arrhythmia in the pre-existing QT-prolongation
  • concomitantly used with azole antifungals [like ketoconazole, itraconazole, miconazole], macrolides [like erythromycin] and quinine.

Precautions

  • Obtain allergy and medication history.
  • Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
  • Use the lowest effective dose for the shortest appropriate duration.
  • Monitor for expected class adverse effects.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Adult and children above 6 yrs: Orally, 10mg OD. Children 2-6 yrs: Orally, 5 mg OD. Children 1-2 years: Orally, 2.5 mg OD. Reduce dose in severe renal failure.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

03 Clinical use

Use, effects & interactions

Indications

  • Allergic rhinnitis
  • chronic urticaria and other allergic conditions
  • treatment adjunct in asthma.
  • Clinical selection for Loratadine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Therapeutic agent (verify pharmacological class).
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • Adverse reactions vary by agent.
  • Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
  • Report suspected ADRs via national pharmacovigilance channels.
  • Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
  • Document allergy status and key interactions.
04 Pharmacology

Mechanism & disposition

An antihistamine with poor blood-brain barrier penetration.

Stimulate β2 receptors↑ cAMPBronchodilation
Read complete mechanism

An antihistamine with poor blood-brain barrier penetration. It has no significant anti-cholinergic activity but it has mild bronchodilator effect. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.

Onset

Product-specific

Duration

Product-specific

Route

See product SmPC

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

FromKES 200
MedianKES 200
Listings2
BrandManufacturerPackObserved price
LORATIN FAST TABS 100`S Not recorded — KES 913.75Daima Chemist price-list reference ↗ Source date not recorded · verify current price
LORHISTINA DAIMA BIASHARA / Wholesale Import TABS 10MG 30`S KES 199.95Daima Chemist price-list reference ↗ Source date not recorded · verify current price
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Professional class pharmacology (Therapeutic agent (verify pharmacological class))
Last reviewed14 Aug 2026
EvidenceGeneral guidance

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.